Joaquim Bosch-Barrera

Summary

Country: Spain

Publications

  1. ncbi Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
  2. ncbi Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
  3. ncbi Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
  4. ncbi Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
  5. ncbi Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
  6. ncbi Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
  7. ncbi Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011

Collaborators

  • Javier A Menendez
  • Jorge Joven
  • Catherine Van Poznak
  • Sílvia Cufí
  • Cristina Oliveras-Ferraros
  • Alejandro Vazquez-Martin
  • Begoña Martin-Castillo
  • Sonia del Barco
  • Rafael de Llorens
  • Christina Oliveras-Ferraros
  • Octavio J Menendez
  • Rosa Quirantes
  • Joan Brunet
  • Vicente Micol
  • Anna Massaguer Vall-Llovera
  • Antonio Segura-Carretero
  • Luciano Vellon
  • Joan Dorca
  • Bernardo Queralt
  • Bruna Corominas-Faja
  • Dolors Carrion Salip

Detail Information

Publications7

  1. ncbi Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
    ..Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed...
  2. ncbi Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
    ..These considerations have been examined from the perspective of a national public healthcare system...
  3. ncbi Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
    ....
  4. ncbi Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
    ..Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin...
  5. ncbi Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
    ....
  6. ncbi Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
    ....
  7. ncbi Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
    ..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...